Amunix Pharmaceuticals, Inc

Augmenta Biosciences, Inc.

John Beaber

Volker Schellenberger

Fan Yang

Vladimir Podust

Bee-Cheng Sim

Christopher J Emig

Marco Antonio Mena

Desiree Thayer

Steven C Henry

Payam Shahi

Rosanna Man Wah Chau

Kim-Xuan Nguyen

YuShuan Lai

The present invention relates to activatable recombinant polypeptide compositions comprising a cleavage release segment. In some instances, the activatable recombinant polypeptide compositions include an XTEN linked to binding moieties by cleavable release segments that, when cleaved, the binding moieties are capable of binding together effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable activatable recombinant compositions.

Release segments and binding compositions comprising same

The disclosure relates generally to the field of immune binding proteins and method for obtaining immune binding proteins from genomic or other sources. The disclosure also relates to anti-SARS-CoV-2 antibodies that have been obtained from subjects who became immune to this coronavirus, and to methods of using these anti-SARS-CoV-2 antibodies. Methods for neutralizing SARS-CoV-2 are disclosed, as well treatments for SARS-COV-2 using the anti-SARS-CoV-2 antibodies.

Antibodies for SARS-CoV-2 and uses thereof

Growing community of inventors

Redwood City, CA, United States of America

John Beaber